News
AMRN
15.20
+4.47%
0.65
Amarin schedules quarterly results release, conference call
PUBT · 19h ago
Weekly Report: what happened at AMRN last week (0406-0410)?
Weekly Report · 2d ago
Amarin announces annual shareholder meeting
Reuters · 5d ago
Wi2Wi FY25 net loss widens to $1.72 million; revenue flat at $6.34 million
Reuters · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Reuters · 04/08 15:51
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Reuters · 04/08 13:15
Amarin says REDUCE-IT post hoc analysis shows Vascepa cuts events in highest-risk patients
Reuters · 04/08 12:04
AMERICAN COLLEGE OF CARDIOLOGY (ACC) SCIENTIFIC SESSIONS 2026 UNDERSCORE THE NEED FOR COMPLEMENTARY THERAPIES INCLUDING ICOSAPENT ETHYL (IPE) IN TREATMENT OF ELEVATED TRIGLYCERIDES AND CARDIOVASCULAR RISK REDUCTION
Reuters · 04/08 12:00
Weekly Report: what happened at AMRN last week (0330-0403)?
Weekly Report · 04/06 09:25
Weekly Report: what happened at AMRN last week (0323-0327)?
Weekly Report · 03/30 09:25
Amarin Streamlines Board, Updates Director Equity Compensation Plan
TipRanks · 03/27 22:27
Amarin board shrinks to seven directors; Paul Cohen and Oliver O'Connor exit ahead of 2026 annual meeting
Reuters · 03/27 21:01
Weekly Report: what happened at AMRN last week (0316-0320)?
Weekly Report · 03/23 09:24
Amarin highlights new recommendation for treatment of CV risk
TipRanks · 03/18 12:41
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Benzinga · 03/18 12:33
Amarin cites 2026 ACC/AHA dyslipidemia guideline support for icosapent ethyl in statin-treated patients with elevated triglycerides
Reuters · 03/18 12:32
Amarin to present data in patients at extreme cardiovascular risk
TipRanks · 03/16 12:27
Amarin to present new REDUCE-IT subgroup analysis of icosapent ethyl at ACC 2026
Reuters · 03/16 12:15
Weekly Report: what happened at AMRN last week (0309-0313)?
Weekly Report · 03/16 09:24
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual
Barchart · 03/16 07:15
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.